{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:51:35Z","timestamp":1789595495164,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"DOI":"10.1186\/s12913-024-11850-y","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T02:22:57Z","timestamp":1732069377000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Distribution and predictors of haemophilia-related costs in the United Kingdom: analysis of the CHESS I and CHESS II burden of illness studies"],"prefix":"10.1186","volume":"24","author":[{"given":"Ione","family":"Woollacott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Chhabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Brownrigg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Ferri Grazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"O\u2019Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josie","family":"Godfrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Laffan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,20]]},"reference":[{"key":"11850_CR1","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1111\/jth.13491","volume":"14","author":"F Peyvandi","year":"2016","unstructured":"Peyvandi F, Garagiola I, Biguzzi E. Advances in the treatment of bleeding disorders. J Thromb Haemost Blackwell Publishing Ltd. 2016;14:2095\u2013106.","journal-title":"J Thromb Haemost Blackwell Publishing Ltd"},{"key":"11850_CR2","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1111\/jth.12672","volume":"12","author":"VS Blanchette","year":"2014","unstructured":"Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12:1935\u20139.","journal-title":"J Thromb Haemost"},{"key":"11850_CR3","doi-asserted-by":"crossref","unstructured":"Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, Carcao M, Mahlangu J, Ragni MV, Windyga J, Llin\u00e1s A, Goddard NJ, Mohan R, Poonnoose PM, Feldman BM, Lewis SZ, Berg HM, Pierce GF. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 2020;26:1\u2013158.","DOI":"10.1111\/hae.14046"},{"key":"11850_CR4","doi-asserted-by":"publisher","unstructured":"Castaman G, Coppens M, Pipe SW. Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B. Expert Rev Hematol. 2023;16(12):919\u201332. https:\/\/doi.org\/10.1080\/17474086.2023.2276206.","DOI":"10.1080\/17474086.2023.2276206"},{"key":"11850_CR5","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/jth.14124","volume":"16","author":"S Hassan","year":"2018","unstructured":"Hassan S, Cannav\u00f2 A, Gouw SC, Rosendaal FR, van der Bom JG. Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review. J Thromb Haemost Elsevier. 2018;16:1055\u201368.","journal-title":"J Thromb Haemost Elsevier"},{"key":"11850_CR6","doi-asserted-by":"publisher","first-page":"540","DOI":"10.7326\/M19-1208","volume":"171","author":"A Iorio","year":"2019","unstructured":"Iorio A, Stonebraker JS, Chambost H, Makris M, Coffin D, Herr C, Germini F. Establishing the prevalence and prevalence at birth of Hemophilia in males: a Meta-analytic Approach using National registries. Ann Intern Med United States. 2019;171:540\u20136.","journal-title":"Ann Intern Med United States"},{"key":"11850_CR7","unstructured":"United Kingdom Haemophilia Centres Doctors\u2019 Organisation, National Haemophilia Database. UKHCDO Annual Report 2023 & Bleeding Disorder Statistics for the Financial Year 2022\/2023. 2023."},{"key":"11850_CR8","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10198-016-0785-2","volume":"17","author":"M Cavazza","year":"2016","unstructured":"Cavazza M, Kodra Y, Armeni P, De Santis M, L\u00f3pez-Bastida J, Linertov\u00e1 R, Oliva-Moreno J, Serrano-Aguilar P, Posada-de-la-Paz M, Taruscio D, Schieppati A, Iskrov G, Gul\u00e1csi L, von der Schulenburg JMG, Kanavos P, Chevreul K, Persson U, Fattore G. Social\/economic costs and quality of life in patients with haemophilia in Europe. Eur J Health Econ Ger. 2016;17:53\u201365.","journal-title":"Eur J Health Econ Ger"},{"key":"11850_CR9","doi-asserted-by":"publisher","first-page":"150","DOI":"10.5482\/HAMO-16-12-0047","volume":"38","author":"K Holstein","year":"2018","unstructured":"Holstein K, von Mackensen S, Bokemeyer C, Langer F. The impact of bleeding disorders on the socioeconomic status of adult patients. Hamostaseologie Ger. 2018;38:150\u20137.","journal-title":"Hamostaseologie Ger"},{"key":"11850_CR10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12955-018-0908-9","volume":"16","author":"J O\u2019Hara","year":"2018","unstructured":"O\u2019Hara J, Walsh S, Camp C, Mazza G, Carroll L, Hoxer C, Wilkinson L. The impact of severe haemophilia and the presence of target joints on health-related quality-of-life. Health Qual Life Outcomes. 2018;16:84.","journal-title":"Health Qual Life Outcomes"},{"key":"11850_CR11","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1182\/bloodadvances.2019001311","volume":"4","author":"BB Warren","year":"2020","unstructured":"Warren BB, Thornhill D, Stein J, Fadell M, Ingram JD, Funk S, Norton KL, Lane HD, Bennett CM, Dunn A, Recht M, Shapiro A, Manco-Johnson MJ. Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the joint outcome continuation study. Blood Adv. 2020;4:2451\u20139.","journal-title":"Blood Adv"},{"key":"11850_CR12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/hae.13616","volume":"25","author":"MJ Scott","year":"2019","unstructured":"Scott MJ, Xiang H, Hart DP, Palmer B, Collins PW, Stephensen D, Sima CS, Hay CRM. Treatment regimens and outcomes in severe and moderate haemophilia A in the UK: the THUNDER study. Haemoph off J World Fed Hemoph Engl. 2019;25:205\u201312.","journal-title":"Haemoph off J World Fed Hemoph Engl"},{"issue":"Suppl 3","key":"11850_CR13","first-page":"s567","volume":"12","author":"Y Kodra","year":"2014","unstructured":"Kodra Y, Cavazza M, Schieppati A, De Santis M, Armeni P, Arcieri R, Calizzani G, Fattore G, Manzoli L, Mantovani L, Taruscio D. The social burden and quality of life of patients with haemophilia in Italy. Blood Transfus Trasfus Sangue. 2014;12(Suppl 3):s567\u201375.","journal-title":"Blood Transfus Trasfus Sangue"},{"key":"11850_CR14","first-page":"e322","volume":"24","author":"J Booth","year":"2018","unstructured":"Booth J, Oladapo A, Walsh S, O\u2019Hara J, Carroll L, Garcia Diego DA, O\u2019Mahony B. Real-world comparative analysis of bleeding complications and health-related quality of life in patients with haemophilia A and haemophilia B. Haemoph Blackwell Publishing Ltd. 2018;24:e322\u20137.","journal-title":"Haemoph Blackwell Publishing Ltd"},{"key":"11850_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-021-02091-x","volume":"17","author":"I Rodriguez-Santana","year":"2022","unstructured":"Rodriguez-Santana I, DasMahapatra P, Burke T, Hakimi Z, Bartelt-Hofer J, Nazir J, O\u2019Hara J. Health-related quality of life, direct medical and societal costs among children with moderate or severe haemophilia in Europe: multivariable models of the CHESS-PAEDs study. Orphanet J Rare Dis BioMed Cent. 2022;17:1\u20139.","journal-title":"Orphanet J Rare Dis BioMed Cent"},{"key":"11850_CR16","doi-asserted-by":"publisher","unstructured":"Burke T, Rodriguez-Santana I, Chowdary P, et al. Humanistic burden of problem joints for children and adults with haemophilia. Haemophilia. 2023;29(2):608\u201318. https:\/\/doi.org\/10.1111\/hae.14731.","DOI":"10.1111\/hae.14731"},{"key":"11850_CR17","first-page":"35","volume":"25","author":"J O\u2019Hara","year":"2019","unstructured":"O\u2019Hara J, Khair K, McLaughlin P, O\u2019Mahony B, Laffan M, Pasi KJ, Chowdary P, Curtis R, Skinner M, Noone D, Willan J, Burke T. Problem Joint a more patient relevant definition for joint morbidity in haemophilia (P154) - poster presentations. Haemoph John Wiley Sons Ltd. 2019;25:35\u2013188.","journal-title":"Haemoph John Wiley Sons Ltd"},{"key":"11850_CR18","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1080\/17474086.2018.1489719","volume":"11","author":"G Castaman","year":"2018","unstructured":"Castaman G. The benefits of prophylaxis in patients with hemophilia B. Expert Rev Hematol. 2018;11:673\u201383.","journal-title":"Expert Rev Hematol"},{"key":"11850_CR19","doi-asserted-by":"publisher","first-page":"e375","DOI":"10.1111\/hae.13019","volume":"22","author":"K Fischer","year":"2016","unstructured":"Fischer K, Lewandowski D, Janssen MP. Modelling lifelong effects of different prophylactic treatment strategies for severe haemophilia A. Haemophilia. 2016;22:e375\u201382.","journal-title":"Haemophilia"},{"key":"11850_CR20","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1182\/blood-2016-02-683169","volume":"129","author":"MJ Manco-Johnson","year":"2017","unstructured":"Manco-Johnson MJ, Soucie JM, Gill JC. Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project. Blood. 2017;129:2368\u201374.","journal-title":"Blood"},{"key":"11850_CR21","first-page":"223","volume":"17","author":"M Franchini","year":"2019","unstructured":"Franchini M, Marano G, Pati I, Candura F, Profili S, Veropalumbo E, Masiello F, Catalano L, Piccinini V, Vaglio S, Pupella S, Liumbruno GM. Emicizumab for the treatment of haemophilia A: a narrative review. Blood Transfus Trasfus Sangue. 2019;17:223\u20138.","journal-title":"Blood Transfus Trasfus Sangue"},{"key":"11850_CR22","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.jval.2017.04.017","volume":"20","author":"CX Chen","year":"2017","unstructured":"Chen CX, Baker JR, Nichol MB. Economic burden of illness among persons with Hemophilia B from HUGS Vb: examining the Association of Severity and Treatment Regimens with costs and Annual Bleed Rates. Value Health J Int Soc Pharmacoeconomics Outcomes Res United States. 2017;20:1074\u201382.","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res United States"},{"key":"11850_CR23","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1111\/jth.13811","volume":"15","author":"MJ Manco-Johnson","year":"2017","unstructured":"Manco-Johnson MJ, Lundin B, Funk S, Peterfy C, Raunig D, Werk M, Kempton CL, Reding MT, Goranov S, Gercheva L, Rusen L, Uscatescu V, Pierdominici M, Engelen S, Pocoski J, Walker D, Hong W. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. J Thromb Haemost. 2017;15:2115\u201324.","journal-title":"J Thromb Haemost"},{"key":"11850_CR24","doi-asserted-by":"crossref","unstructured":"Li N, Sawyer EK, Maruszczyk K, Slomka M, Burke T, Martin AP, O\u2019Hara J, editors. Economic burden of hemophilia B in the US: a systematic literature review. J Drug Assess 2019;8:28.","DOI":"10.1080\/21556660.2019.1658306"},{"key":"11850_CR25","first-page":"2118","volume":"134","author":"D Noone","year":"2019","unstructured":"Noone D, Pedra G, Asghar S, O\u2019Hara J, Sawyer EK, Li N, Nick. Prophylactic treatment in people with severe Hemophilia B in the US: an analysis of Real-World Healthcare System costs and clinical outcomes. Blood Am Soc Hematol. 2019;134:2118\u20132118.","journal-title":"Blood Am Soc Hematol"},{"key":"11850_CR26","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13023-017-0660-y","volume":"12","author":"J O\u2019Hara","year":"2017","unstructured":"O\u2019Hara J, Hughes D, Camp C, Burke T, Carroll L, Diego DAG. The cost of severe haemophilia in Europe: the CHESS study. Orphanet J Rare Dis. 2017;12:106.","journal-title":"Orphanet J Rare Dis"},{"key":"11850_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13696998.2022.2049552","volume":"25","author":"T Burke","year":"2022","unstructured":"Burke T, Shaikh A, Ali TM, Li N, Curtis R, Garcia Diego D-A, Recht M, Sannie T, Skinner M, O\u2019Hara J. Association of factor expression levels with health-related quality of life and direct medical costs for people with haemophilia B. J Med Econ. 2022;25:1\u201321.","journal-title":"J Med Econ."},{"key":"11850_CR28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-021-02091-x","volume":"17","author":"I Rodriguez-Santana","year":"2022","unstructured":"Rodriguez-Santana I, DasMahapatra P, Burke T, Hakimi Z, Bartelt-Hofer J, Nazir J, O\u2019Hara J. Differential humanistic and economic burden of mild, moderate and severe haemophilia in European adults: a regression analysis of the CHESS II study. Orphanet J Rare Dis BioMed Cent. 2022;17:1\u201310.","journal-title":"Orphanet J Rare Dis BioMed Cent"},{"key":"11850_CR29","first-page":"s126","volume":"22","author":"S-L Chen","year":"2016","unstructured":"Chen S-L. Economic costs of hemophilia and the impact of prophylactic treatment on patient management. Am J Manag Care. 2016;22:s126\u201333.","journal-title":"Am J Manag Care"},{"key":"11850_CR30","first-page":"316","volume":"27","author":"SE Croteau","year":"2021","unstructured":"Croteau SE, Cook K, Sheikh L, Chawla A, Sammon J, Solari P, Kim B, Hinds D, Thornburg CD. Health care resource utilization and costs among adult patients with hemophilia A on factor VIII prophylaxis: an administrative claims analysis. J Manag Care Spec Pharm United States. 2021;27:316\u201326.","journal-title":"J Manag Care Spec Pharm United States"},{"key":"11850_CR31","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3111\/13696998.2015.1016228","volume":"18","author":"Z-Y Zhou","year":"2015","unstructured":"Zhou Z-Y, Koerper MA, Johnson KA, Riske B, Baker JR, Ullman M, Curtis RG, Poon J-L, Lou M, Nichol MB. Burden of illness: direct and indirect costs among persons with hemophilia A in the United States. J Med Econ Engl. 2015;18:457\u201365.","journal-title":"J Med Econ Engl"},{"key":"11850_CR32","first-page":"632","volume":"24","author":"T Thorat","year":"2018","unstructured":"Thorat T, Neumann PJ, Chambers JD. Hemophilia Burden of Disease: a systematic review of the cost-utility literature for Hemophilia. J Manag Care Spec Pharm. 2018;24:632\u201342.","journal-title":"J Manag Care Spec Pharm"},{"key":"11850_CR33","first-page":"643","volume":"24","author":"BJ Tortella","year":"2018","unstructured":"Tortella BJ, Alvir J, McDonald M, Spurden D, Fogarty PF, Chhabra A, Pleil AM. Real-world analysis of dispensed IUs of Coagulation factor IX and resultant expenditures in Hemophilia B patients receiving standard half-life Versus Extended Half-Life products and those switching from Standard Half-Life to Extended Half-Life products. J Manag Care Spec Pharm. 2018;24:643\u201353.","journal-title":"J Manag Care Spec Pharm"},{"key":"11850_CR34","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","volume":"15","author":"B van Hout","year":"2012","unstructured":"van Hout B, Janssen MF, Feng Y-S, Kohlmann T, Busschbach J, Golicki D, Lloyd A, Scalone L, Kind P, Pickard AS. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2012;15:708\u201315.","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res."},{"key":"11850_CR35","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40273-022-01218-7","volume":"41","author":"M Hern\u00e1ndez Alava","year":"2023","unstructured":"Hern\u00e1ndez Alava M, Pudney S, Wailoo A. Estimating the relationship between EQ-5D-5L and EQ-5D-3L: results from a UK Population Study. PharmacoEconomics. 2023;41:199\u2013207.","journal-title":"PharmacoEconomics"},{"key":"11850_CR36","doi-asserted-by":"crossref","unstructured":"Szende A, Janssen B, Cabases J, editors. Self-reported Population Health: An International Perspective based on EQ-5D. Dordrecht: Springer; 2014.","DOI":"10.1007\/978-94-007-7596-1"},{"key":"11850_CR37","doi-asserted-by":"publisher","unstructured":"Shaikh A, Pedra G, Cawson M, Wiseman C. Examining the impact of haemophilia treatment on health-related quality of life. Haemophilia. 2022;28(5):796\u2013805. https:\/\/doi.org\/10.1111\/hae.14583.","DOI":"10.1111\/hae.14583"},{"key":"11850_CR38","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/hae.13111","volume":"23","author":"E Berntorp","year":"2017","unstructured":"Berntorp E, Dolan G, Hay C, Linari S, Santagostino E, Tosetto A, Castaman G, \u00c1lvarez-Rom\u00e1n MT, Parra Lopez R, Oldenburg J, Albert T, Scholz U, Holmstr\u00f6m M, Schved JF, Trossa\u00ebrt M, Hermans C, Boban A, Ludlam C, Lethagen S. European retrospective study of real-life haemophilia treatment. Haemophilia. 2017;23:105\u201314.","journal-title":"Haemophilia"},{"key":"11850_CR39","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/bjh.16704","volume":"190","author":"R Rayment","year":"2020","unstructured":"Rayment R, Chalmers E, Forsyth K, Gooding R, Kelly AM, Shapiro S, Talks K, Tunstall O, Biss T. British Society for Haematology. Guidelines on the use of prophylactic factor replacement for children and adults with Haemophilia A and B. Br J Haematol. 2020;190:684\u201395.","journal-title":"Br J Haematol"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-024-11850-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-024-11850-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-024-11850-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T03:05:35Z","timestamp":1732071935000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-024-11850-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,20]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["11850"],"URL":"https:\/\/doi.org\/10.1186\/s12913-024-11850-y","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,20]]},"assertion":[{"value":"9 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The CHESS I and CHESS II studies were approved by the Research Ethics Sub Committee of the Faculty of Health and Social care within the University of Chester and conducted in correspondence with regional and relevant guidelines. Patient consent for use of clinical data was not required (as per European Pharmaceutical Market Research Association [EPhMRA] guidelines). Patient consent was obtained via tick box selection for the patient-reported element of the studies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study was sponsored by Pfizer Ltd. TB and EFG are employees of HCD Economics Ltd., which was a paid consultant to Pfizer Ltd. in connection with the development of this manuscript and for study design, data analysis and interpretation. EFG: Speakers\u2019 bureau: Sobi, Roche, Novo Nordisk, BioMarin, CSL Behring; Advisory boards: Sobi, Roche, BioMarin, Pfizer. IW and LR are employees of Pfizer Ltd., the study sponsor.\u00a0JOH was an employee of HCD Economics Ltd. during the conduct of the study. IW, AC, JB and LR were employees of Pfizer Ltd. during the conduct of this study. JB is currently employed by BioMarin Pharmaceutical Inc. ML was a paid consultant to Pfizer Ltd. in relation to study design and data interpretation for this study and also declares the following: Consultant to AstraZeneca, Silence, Hemab; Research grant support from BioMarin; Speaker fees from Pfizer, Bayer, Takeda, Leo Pharma, Sobi, AstraZeneca, Chugai\/Roche; Advisory boards: Takeda, LFB, Roche\/Chugai, Sobi, Bayer, Pfizer, CSL Behring, BioMarin. JG was a paid consultant to Pfizer Ltd. in relation to study design and data interpretation for this study and has been a paid consultant to HCD Economics Ltd. in relation to a separate haemophilia study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1437"}}